{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-190764","form_type":"8-K","ticker":null,"cik":"0001805387","company_name":"Cerevel Therapeutics Holdings, Inc.","filed_at":"2024-08-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.583774+00:00","generated_at":"2026-05-31T13:56:42.412682+00:00","sec_items":["1.01","2.01","3.01","3.03","5.01","5.02","5.03","8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":1.0,"calibrated_materiality_score":1.0,"confidence":"high","headline":"AbbVie completes $45/share acquisition of Cerevel; Cerevel becomes wholly owned subsidiary","bullets":["Cerevel stockholders received $45.00 per share in cash for each share; total consideration not disclosed.","All 12 board members resigned; Scott Reents (from Merger Sub) becomes sole director.","Cerevel shares ceased trading on Nasdaq effective August 1, 2024; deregistration to follow.","AbbVie reaffirms FY2024 adjusted EPS guidance of $10.71-$10.91, including $0.19 dilutive impact from deal.","Key assets: emraclidine (schizophrenia, Phase 2 registration-enabling), tavapadon (Parkinson's, Phase 3 met primary endpoint)."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-190764","json":"https://secwatch.observer/filing/0001193125-24-190764.json","markdown":"https://secwatch.observer/filing/0001193125-24-190764.md","text":"https://secwatch.observer/filing/0001193125-24-190764.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1805387/000119312524190764/0001193125-24-190764-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1805387/000119312524190764/d814318d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T13:56:42.412682+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"056b3f594c","claim":"Douglas Giordano resigned as Director at Cerevel Therapeutics Holdings, Inc..","evidence_excerpt":"each of the directors of Cerevel (Tony Coles, M.D., Ron Renaud, Marijn Dekkers, Ph.D., Douglas Giordano, Chris Gordon, Adam Koppel, M.D., Ph.D., Norbert Riedel, Ph.D., Gabrielle Sulzberger, Ruth McKernan, Ph.D., Deval Patrick, Deborah Baron and Suneet Varma) resigned from the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1805387/000119312524190764/0001193125-24-190764-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"1094bbd25e","claim":"Adam Koppel, M.D., Ph.D. resigned as Director at Cerevel Therapeutics Holdings, Inc..","evidence_excerpt":"each of the directors of Cerevel (Tony Coles, M.D., Ron Renaud, Marijn Dekkers, Ph.D., Douglas Giordano, Chris Gordon, Adam Koppel, M.D., Ph.D., Norbert Riedel, Ph.D., Gabrielle Sulzberger, Ruth McKernan, Ph.D., Deval Patrick, Deborah Baron and Suneet Varma) resigned from the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1805387/000119312524190764/0001193125-24-190764-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"341cf485e9","claim":"Marijn Dekkers, Ph.D. resigned as Director at Cerevel Therapeutics Holdings, Inc..","evidence_excerpt":"each of the directors of Cerevel (Tony Coles, M.D., Ron Renaud, Marijn Dekkers, Ph.D., Douglas Giordano, Chris Gordon, Adam Koppel, M.D., Ph.D., Norbert Riedel, Ph.D., Gabrielle Sulzberger, Ruth McKernan, Ph.D., Deval Patrick, Deborah Baron and Suneet Varma) resigned from the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1805387/000119312524190764/0001193125-24-190764-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"4a8fa8daff","claim":"Deval Patrick resigned as Director at Cerevel Therapeutics Holdings, Inc..","evidence_excerpt":"each of the directors of Cerevel (Tony Coles, M.D., Ron Renaud, Marijn Dekkers, Ph.D., Douglas Giordano, Chris Gordon, Adam Koppel, M.D., Ph.D., Norbert Riedel, Ph.D., Gabrielle Sulzberger, Ruth McKernan, Ph.D., Deval Patrick, Deborah Baron and Suneet Varma) resigned from the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1805387/000119312524190764/0001193125-24-190764-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"6f73b27a04","claim":"Tony Coles, M.D. resigned as Director at Cerevel Therapeutics Holdings, Inc..","evidence_excerpt":"each of the directors of Cerevel (Tony Coles, M.D., Ron Renaud, Marijn Dekkers, Ph.D., Douglas Giordano, Chris Gordon, Adam Koppel, M.D., Ph.D., Norbert Riedel, Ph.D., Gabrielle Sulzberger, Ruth McKernan, Ph.D., Deval Patrick, Deborah Baron and Suneet Varma) resigned from the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1805387/000119312524190764/0001193125-24-190764-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"7e8e04e8ef","claim":"Scott T. Reents was appointed as Director at Cerevel Therapeutics Holdings, Inc..","evidence_excerpt":"Scott T. Reents, the sole director of Merger Sub immediately prior to the Effective Time, became the sole director of Cerevel.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1805387/000119312524190764/0001193125-24-190764-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"8cc1477f39","claim":"Ruth McKernan, Ph.D. resigned as Director at Cerevel Therapeutics Holdings, Inc..","evidence_excerpt":"each of the directors of Cerevel (Tony Coles, M.D., Ron Renaud, Marijn Dekkers, Ph.D., Douglas Giordano, Chris Gordon, Adam Koppel, M.D., Ph.D., Norbert Riedel, Ph.D., Gabrielle Sulzberger, Ruth McKernan, Ph.D., Deval Patrick, Deborah Baron and Suneet Varma) resigned from the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1805387/000119312524190764/0001193125-24-190764-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"963b28accf","claim":"Gabrielle Sulzberger resigned as Director at Cerevel Therapeutics Holdings, Inc..","evidence_excerpt":"each of the directors of Cerevel (Tony Coles, M.D., Ron Renaud, Marijn Dekkers, Ph.D., Douglas Giordano, Chris Gordon, Adam Koppel, M.D., Ph.D., Norbert Riedel, Ph.D., Gabrielle Sulzberger, Ruth McKernan, Ph.D., Deval Patrick, Deborah Baron and Suneet Varma) resigned from the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1805387/000119312524190764/0001193125-24-190764-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"b23e431eaa","claim":"Suneet Varma resigned as Director at Cerevel Therapeutics Holdings, Inc..","evidence_excerpt":"each of the directors of Cerevel (Tony Coles, M.D., Ron Renaud, Marijn Dekkers, Ph.D., Douglas Giordano, Chris Gordon, Adam Koppel, M.D., Ph.D., Norbert Riedel, Ph.D., Gabrielle Sulzberger, Ruth McKernan, Ph.D., Deval Patrick, Deborah Baron and Suneet Varma) resigned from the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1805387/000119312524190764/0001193125-24-190764-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"bdd5c06056","claim":"Ron Renaud resigned as Director at Cerevel Therapeutics Holdings, Inc..","evidence_excerpt":"each of the directors of Cerevel (Tony Coles, M.D., Ron Renaud, Marijn Dekkers, Ph.D., Douglas Giordano, Chris Gordon, Adam Koppel, M.D., Ph.D., Norbert Riedel, Ph.D., Gabrielle Sulzberger, Ruth McKernan, Ph.D., Deval Patrick, Deborah Baron and Suneet Varma) resigned from the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1805387/000119312524190764/0001193125-24-190764-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"ddf158ab9c","claim":"Norbert Riedel, Ph.D. resigned as Director at Cerevel Therapeutics Holdings, Inc..","evidence_excerpt":"each of the directors of Cerevel (Tony Coles, M.D., Ron Renaud, Marijn Dekkers, Ph.D., Douglas Giordano, Chris Gordon, Adam Koppel, M.D., Ph.D., Norbert Riedel, Ph.D., Gabrielle Sulzberger, Ruth McKernan, Ph.D., Deval Patrick, Deborah Baron and Suneet Varma) resigned from the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1805387/000119312524190764/0001193125-24-190764-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"defa609378","claim":"Deborah Baron resigned as Director at Cerevel Therapeutics Holdings, Inc..","evidence_excerpt":"each of the directors of Cerevel (Tony Coles, M.D., Ron Renaud, Marijn Dekkers, Ph.D., Douglas Giordano, Chris Gordon, Adam Koppel, M.D., Ph.D., Norbert Riedel, Ph.D., Gabrielle Sulzberger, Ruth McKernan, Ph.D., Deval Patrick, Deborah Baron and Suneet Varma) resigned from the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1805387/000119312524190764/0001193125-24-190764-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"ef76dd707e","claim":"Chris Gordon resigned as Director at Cerevel Therapeutics Holdings, Inc..","evidence_excerpt":"each of the directors of Cerevel (Tony Coles, M.D., Ron Renaud, Marijn Dekkers, Ph.D., Douglas Giordano, Chris Gordon, Adam Koppel, M.D., Ph.D., Norbert Riedel, Ph.D., Gabrielle Sulzberger, Ruth McKernan, Ph.D., Deval Patrick, Deborah Baron and Suneet Varma) resigned from the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1805387/000119312524190764/0001193125-24-190764-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}